With consistent efficacy associated with contemporary antiretroviral therapy (ART),1 many clinicians have shifted their focus to assessing patient reported outcomes (PROs) – the impact of medication(s) on an individual’s overall health and sense of wellbeing - in order to differentiate between treatment regimens.
In the final instalment of this three-part series, Dr Martin discusses the use of patient reported outcomes (PROs) in HIV research and the importance of using adequately validated tools.
Amid the growing use of quality measures, patient-reported outcomes (PROs) should not be overlooked as a potential tool to improve clinical care, according to Dr Hal Martin, Director of Clinical Research at Gilead Sciences, San Francisco, California. In this second of a three-part series, Dr Martin discusses how PRO questionnaires can be used in practice to more accurately identify issues faced by people living with HIV (PLHIV).
This is the first in a three-part series on patient reported outcomes (PROs) and how they can be incorporated into the clinical management of people living with HIV (PLHIV). The series includes expert insights from Dr Hal Martin, Director of Clinical Research at Gilead Sciences, San Francisco, California, and includes a link to the HIV Symptom Index – the most commonly used instrument to measure PROs in PLHIV.
As the treatment and management of people living with HIV (PLHIV) continues to evolve, the most updated versions of guidelines should be consulted. Guidelines issued by US Department of Health and Human Services (DHHS) and the European AIDS Clinical Society (EACS) are commonly used by HIV clinicians and are routinely updated to reflect the current literature.
New US and EU guidelines recommend Gilead’s BIKTARVY®▼ (bictegravir / emtricitabine / tenofovir alafenamide)
In October 2018, the US Department of Health and Human Services (DHHS) and the European AIDS Clinical Society (EACS) released new guidelines for the management of people living with HIV (PLHIV). Both guidelines incorporated Gilead’s once-daily, single tablet regimen (STR), BIKTARVY®, which comprises an integrase strand transfer inhibitor [INSTI; bictegravir (BIC)] combined with two nucleoside reverse transcriptase inhibitors [NRTIs; emtricitabine (FTC) and tenofovir alafenamide (TAF)].1-3
Results from a real-world study show reassuring improvements in renal function after switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)*1 from E/C/F/tenofovir disoproxil fumarate (E/C/F/TDF) and provide additional clinical evidence that, in comparison to tenofovir disoproxil fumarate (TDF), TAF is associated with significantly less tenofovir (TFV) plasma exposure2,3 and a reduction in off-target effects.4 The findings also concur with guidelines issued by the US Department of Health and Human Services (DHHS).5
A real-world study of treatment-naïve (TN) and treatment-experienced (TE) adults with HIV infection suggests that emtricitabine/tenofovir alafenamide (F/TAF) – based antiretroviral regimens are associated with a high rate of persistence and low rate of discontinuation.1,2
In the third installment of NoCo, this program will fund approximately six to eight projects with a total commitment of US $3M focused on investigating strategies to link patients living with HCV and HIV co-infection to HCV treatment.
Significant advances in HIV treatment and management mean that many people living with HIV (PLHIV) can now expect to live as long as the general population.1